Actively evaluating strategic options for OnkosXcel Therapeutics, including potential partnering or third-party investments.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BTAI:
- BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
- BioXcel Therapeutics to participate in a conference call with Truist
- BioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023
- BioXcel Therapeutics to hold Key Opinion Leader Day
- BioXcel Therapeutics price target raised to $79 from $73 at H.C. Wainwright